IRVINE, Calif., Oct. 19, 2005 (PRIMEZONE) -- "Recent and dramatic stem cell advancements have been met with great volatility in the marketplace," stated SmallCap Sentinel analyst, D.R. Clark. "Stem cell company stock prices have not necessarily benefited from what can be described as historic achievements, as well as potential breakthroughs in resolving moral issues surrounding research. This could well be a condition of the overall market and biotechnology- not simply an indicator of current interest in stem cells."
"Leading companies like StemCells, Inc. have seen pretty wild price swings in the last week. It's clear that some investors see value at recent prices well off 52-week highs while others may be leaving the biotech space," added Clark.
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com
The report will address current stem cell issues as well as examine related companies such as New Life Scientific (OTCBB:NWLF), which endeavors to blend Eastern European research and development with Western management, Genentech, Inc. (NYSE:DNA), Sepracor Inc. (Nasdaq:SEPR) and Celgene Corporation (Nasdaq:CELG) will be discussed in the report.
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid thirty-six hundred dollars for preparation and distribution of this report and other advertising services by Emerging Markets Consulting LLC. An editor of this publication currently holds 1,100 shares of STEM. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.